By Tort Law Team 
Thousands of patients who took Ozempic or similar GLP-1 receptor agonists for diabetes or weight loss later faced severe, life-altering side effects they say no one adequately warned them about. Gastroparesis (often called stomach paralysis), intestinal obstruction, ileus, and sudden vision loss from non-arteritic anterior ischemic optic neuropathy (NAION) have led many to seek legal recourse. If you or a loved one experienced these injuries after using semaglutide products like Ozempic, Wegovy, or Rybelsus, understanding the ozempic lawsuit landscape is the first step toward potential compensation. This guide explains eligibility, the claims being filed, the current status of multidistrict litigation, and practical steps to connect with experienced counsel for a free case evaluation.
Understanding the Ozempic Lawsuit Landscape
Ozempic (semaglutide) and related GLP-1 receptor agonists work by slowing gastric emptying and regulating blood sugar and appetite. That mechanism helps many people manage type 2 diabetes or lose weight. For some, however, the same effect allegedly progressed into serious, persistent harm.
Plaintiffs in the ongoing litigation primarily allege Novo Nordisk failure to warn. They claim the company knew or should have known about risks of severe gastrointestinal injuries and NAION yet did not provide timely or adequate warnings on U.S. labels. Similar claims target Eli Lilly for products such as Mounjaro and Trulicity in certain tracks.
Two separate federal multidistrict litigations (MDLs) now coordinate the bulk of these cases in the Eastern District of Pennsylvania before Judge Karen S. Marston:
- MDL 3094 covers gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction. As of early October 2026, more than 4,000 cases were pending.
- MDL 3163, created in December 2025, addresses NAION vision-loss claims and held roughly 247 pending actions around the same time.
These consolidated proceedings allow efficient handling of shared scientific and legal questions while preserving each plaintiff’s individual claim. No global settlements or jury verdicts had been announced by October 2026. The litigation remains in pretrial stages focused on expert evidence, causation, and preemption issues.
European regulators added NAION as a “very rare” side effect of semaglutide medicines in 2025. U.S. labels still lack a specific NAION warning as of late 2026, a point plaintiffs highlight in failure-to-warn arguments. For gastrointestinal risks, the FDA updated the Ozempic label over time. Ileus appeared in postmarketing language in 2023. A stronger statement that the drug is not recommended in patients with severe gastroparesis was added in October 2025.
Common Injuries Driving Ozempic Lawsuits
Gastroparesis and Stomach Paralysis
Gastroparesis occurs when the stomach empties food too slowly or stops moving it into the small intestine, even without a mechanical blockage. Patients often describe relentless nausea, vomiting after small meals, bloating, early satiety, abdominal pain, and unintended weight loss or malnutrition. Some require repeated hospitalizations, feeding tubes, or long-term dietary restrictions.
In August 2025, Judge Marston ruled that plaintiffs claiming drug-induced gastroparesis generally need objective confirmation through a gastric emptying study (such as scintigraphy, breath test, or wireless motility capsule) performed around the time of diagnosis. Symptoms alone are typically not enough to sustain a gastroparesis claim in the MDL. Many people diagnosed clinically never received the formal test, so reviewing medical records carefully is essential.
Ileus and Intestinal Obstruction
Ileus and bowel obstruction involve the intestines failing to propel contents forward. Symptoms can include severe abdominal pain, constipation, inability to pass gas, vomiting, and distension. These conditions often lead to emergency room visits or surgery. Objective evidence usually comes from CT scans, X-rays, endoscopy, or operative findings rather than a gastric emptying study.
NAION Vision Loss
Non-arteritic anterior ischemic optic neuropathy involves reduced blood flow to the optic nerve, causing sudden, painless vision loss, often noticed upon waking. The loss is frequently permanent and can affect one or both eyes. A 2024 Harvard/Massachusetts Eye and Ear study reported elevated risk among semaglutide users. Subsequent research and European regulatory action have kept the issue in the spotlight. Plaintiffs argue they would have chosen different treatment or undergone closer eye monitoring had they known of the risk.
Other reported issues in some filings include severe prolonged vomiting requiring hospitalization and, in limited circumstances, gallbladder problems. Qualifying criteria can vary by law firm and by track (GI versus vision).
Do I Qualify for an Ozempic Lawsuit?
Eligibility depends on several factors. No single checklist guarantees acceptance, and criteria evolve with court rulings. Common elements attorneys currently examine include:
- Use of brand-name Ozempic, Wegovy, or Rybelsus (semaglutide products from Novo Nordisk). Some firms also review Mounjaro, Zepbound, or Trulicity cases, particularly for NAION claims.
- A medically documented qualifying injury: gastroparesis confirmed by gastric emptying study, ileus or intestinal obstruction confirmed by imaging or surgical findings, or a diagnosed NAION with residual vision impairment.
- Timing that links the drug to the injury (symptoms beginning during use or shortly after discontinuation).
- Supporting medical records showing prescriptions, diagnoses, emergency care, or hospitalizations.
- Filing within the applicable statute of limitations (typically one to four years from discovery of the injury and its potential link to the drug, depending on the state).
Age limits, exclusion of compounded or generic versions, and absence of certain prior conditions appear in some firm intake criteria. Family members of deceased patients may explore wrongful death claims in appropriate cases.
If you are unsure whether your records meet these thresholds, a free case evaluation by an attorney experienced in pharmaceutical litigation can clarify your options. Gathering prescription history, hospital discharge summaries, and test results ahead of time speeds the review.
Legal Claims in Ozempic Litigation
The central theory is product liability based on failure to warn. Plaintiffs allege that Novo Nordisk (and Eli Lilly where applicable) marketed GLP-1 receptor agonists as relatively safe while understating or omitting serious risks of persistent gastroparesis, intestinal blockage, and NAION.
Additional theories sometimes include design defect or negligence, though failure-to-warn remains the dominant claim. Courts examine whether the manufacturer provided adequate information so that doctors and patients could make informed decisions. Label changes over the years form part of the factual backdrop: earlier labels mentioned delayed gastric emptying mainly in the context of drug interactions, while stronger gastrointestinal language appeared later.
Defendants contest both general causation (whether the drugs can cause these injuries) and specific causation (whether the drug caused a particular plaintiff’s injury). They also raise preemption arguments based on FDA approval and labeling. These issues are actively litigated through expert challenges and summary-judgment motions.
How to File an Ozempic Lawsuit: Step-by-Step Process
- Document everything. Collect medical records, prescription bottles or pharmacy printouts, notes about symptom onset, and any communications with doctors about side effects.
- Seek a free case evaluation. Most firms handling these claims offer no-cost, no-obligation reviews. An attorney or intake specialist will assess whether your facts align with current MDL criteria.
- Retain counsel. If the firm accepts your case, you typically sign a contingency-fee agreement. You pay nothing upfront; the firm recovers fees only if compensation is obtained.
- File the complaint. Your attorney prepares and files an individual lawsuit. In federal court it is usually transferred into the appropriate MDL (3094 for GI injuries or 3163 for NAION). Parallel state-court proceedings exist in some jurisdictions, including New Jersey multicounty litigation.
- Participate in discovery. You may complete a plaintiff fact sheet detailing your medical history, drug use, and injuries. Medical records are collected. Expert witnesses on both sides address causation and damages.
- Monitor progress and prepare for resolution. Shared rulings on experts and preemption can shape the path forward. Individual cases may settle, proceed to trial (including potential bellwether trials), or face dismissal depending on the evidence.
Throughout the process, an experienced ozempic vision loss lawyer or gastroparesis attorney handles procedural deadlines, communicates with the court, and protects your interests. Because statutes of limitations continue to run until a case is properly filed, early consultation is wise.
Current Status of Settlements and Litigation Updates
As of October 2026, no global settlement program or individual trial verdicts have been publicly announced in either MDL. MDL 3094 has seen extensive briefing on expert admissibility (Rule 702/Daubert) and summary judgment on various injury categories. A multi-day evidentiary hearing on experts occurred in mid-September 2026; a ruling was pending at last public check. Status conferences continue.
MDL 3163 is at an earlier stage, with a pretrial schedule extending into 2027 for fact discovery, expert reports, and dispositive motions.
Settlement values, if and when they occur, typically turn on the severity and permanence of injury, strength of medical documentation, age of the plaintiff, economic losses (medical bills, lost wages), and non-economic damages such as pain and suffering. Speculation about specific dollar ranges is unreliable at this stage. Any eventual resolution would reflect the unique facts of each claim.
Potential Compensation in an Ozempic Lawsuit
Recoverable damages in successful product-liability claims can include:
- Past and future medical expenses
- Lost income and diminished earning capacity
- Pain, suffering, and loss of enjoyment of life
- In some cases, punitive damages if conduct is found especially egregious
Compensation is never guaranteed. Outcomes depend on the evidence, applicable law, and negotiation or trial results. An attorney can help you understand the realistic range once records are reviewed.
Pitfalls to Avoid When Considering a Claim
Do not ignore statutes of limitations. Missing the deadline can permanently bar recovery. Avoid signing broad releases or accepting small offers without legal advice. Do not delay gathering records; memories fade and documents become harder to obtain. Be cautious of online sources promising fixed settlement amounts; those figures are not grounded in current court records.
Why Patients Are Taking Action
Many people began Ozempic or a related drug hopeful for better blood-sugar control or meaningful weight loss. When severe gastrointestinal symptoms or sudden vision changes appeared, some felt blindsided. The lawsuits reflect a desire for accountability and for better information so future patients can weigh risks more fully. Family members often step in when a loved one is too ill or has passed away, seeking both answers and financial relief for medical costs and lost support.
Frequently Asked Questions
What injuries qualify for an ozempic lawsuit?
Documented gastroparesis confirmed by gastric emptying study, ileus or intestinal obstruction supported by imaging or surgery, and NAION vision loss are the primary injuries currently pursued. Severity, timing, and medical records matter.
Is there an ozempic lawsuit settlement yet?
No global settlement or public payout matrix existed as of October 2026. The cases remain in active pretrial litigation.
How long do I have to file?
Statutes of limitations vary by state, commonly one to four years from the date you knew or reasonably should have known of the injury and its possible connection to the drug. Consult counsel promptly.
Can I still sue if the label now mentions gastroparesis?
Label changes after your use period often strengthen rather than weaken failure-to-warn claims for earlier prescriptions. An attorney can evaluate the timeline specific to your case.
Do I need a gastric emptying study for a gastroparesis claim?
Under the August 2025 ruling in MDL 3094, objective testing around the time of diagnosis is generally required for gastroparesis claims to proceed. Other injuries have different documentation standards.
What if I took Mounjaro or Wegovy instead of Ozempic?
Wegovy (also semaglutide) is frequently included in both tracks. Mounjaro and related tirzepatide products appear more commonly in NAION claims under current criteria used by many firms. Eligibility is case-specific.
Will filing a lawsuit cost me money upfront?
Most pharmaceutical injury firms work on contingency. Fees are paid only if compensation is recovered.
You May Also Like: Affirm Lawsuit Explained: Consumer Rights, Legal Status, and Payout Eligibility